Pipeline

Overview

Innovative pipeline development strategy

Differentiated R&D for Fast New Drug Success and Profitability

  • Pipeline
  • Indication
  • Route of
    Administration
  • Discovery
    Preclinical
    Phase Ⅰ

    Phase Ⅱ

    2a 2b

    Phase Ⅲ
    Launch
  • CU06
    Diabetic Macular Edema
    Oral

    Phase 2a study (us) Clinical Study Reports received in Apr 2024
  • CU06
    Wet-AMD(Age-related Macular Degeneration)
    Oral

    Completed phase 1 study (US) in Jun 2022
  • CU01
    Diabetic Nephropathy
    Oral

    Phase 2b first patient enrolled in Feb 2023
  • MT-101
    AKI(Acute Kidney Injury)/ CKD(Chronic Kidney Disease)
    Injection

    Preclinical study in progress
  • MT-103
    Wet-AMD/DME/Diabetic Retinopathy
    Injection

    Preclinical study in progress
  • Pipeline
  • Indication
  • Route of
    Administration
  • Discovery
    Preclinical
    Phase Ⅰ

    Phase Ⅱ

    2a 2b

    Phase Ⅲ
    Launch
  • CU104
    Ulcerative Colitis
    Oral

    Phase 2 study IND approval(US) in Jun 2023 / IND approval(Europe) in Dec 2023 / IND application(Korea) in Mar 2024
  • CU106
    Immuno-Oncology Combination
    Oral

    Completed phase 1 study (US) in Jun 2022
  • CU03
    Wet-AMD(Age-related Macular Degeneration)
    Oral

    Finalized phase 2 CSR in Jan 2022
  • CU71-R01
    Next-Generation Endothelial Dysfunction Blocker
    Oral

    Discovery
  • CP01-R01
    Kidney Failure in Companion Animals
    Oral

    Preparing for phase 2b/3 study
  • MT-102
    CLI(Critical Limb Ischemia)
    Injection

    Preclinical study in progress
  • MT-104
    Solid Cancer
    Injection

    Discovery
  • MT-105
    IBD(Inflammatory Bowel Disease)
    Injection

    Discovery
  • MT-201
    Inflammatory Thrombosis
    Injection

    Discovery
  • MT-202
    AIS(Acute Ischemic Stroke)
    Injection

    Discovery
  • MT-40X
    Solid Cancer
    Injection

    Discovery